April 18, 2014 7:59 AM ET

Pharmaceuticals

Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers vaccines that include Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used as an additive to influenza vaccines; and SARS (D3252), which is used as an antigen for severe acute respiratory syndrome (SARS) virus. It also provides baculovirus expression vector system for prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applications; expresSF+ cells, and insect cell line that is used in the production of proteins; GeneXpress, which provides ...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983

Phone:

203-686-0800

Fax:

203-686-0268

Key Executives for Protein Sciences Corporation

Chief Executive Officer
Chief Medical Officer
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Age: 72
Compensation as of Fiscal Year 2013.

Protein Sciences Corporation Key Developments

Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM

Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM. Venue: Grand Hyatt, Tokyo, Japan.

Protein Sciences Corporation Announces Availability of Flublok Influenza Vaccine

Protein Sciences Corporation announced that doses for the 2013-14 season have been released by the FDA and are now available. Quantities of Flublok are limited and will be distributed on a first-come, first-served basis exclusively by FFF Enterprises. Flublok, a cutting-edge class of influenza vaccine called RIV3 (recombinant hemagglutinin influenza vaccine, trivalent formulation), is made by making just the active ingredient needed for protection without growing influenza virus. The vaccine contains 3 times the protective ingredient in traditional flu vaccines. The CDC recommends the use of Flublok for all adults 18-49 years old and specifically for those in that age range who have a known or suspected egg allergy, regardless of severity. Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.

Protein Sciences Corporation Announces First Doses of Flublok Influenza Vaccine

Protein Sciences Corporation announced that they expect the first doses of Flublok influenza vaccine for the 2013/2014 season to be released in time for vaccinations to occur prior to Thanksgiving. According to the Centers for Disease Control and Prevention (CDC), influenza activity typically peaks in January or later. It takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, so it is best that people get vaccinated before then. Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.

Similar Private Companies By Industry

Company Name Region
GMP Laboratories of America, Inc. United States
Cenomed BioSciences LLC United States
Clinical Site Services Corporation United States
Edan Naturals LLC United States
Dynova Laboratories, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 25, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Sciences Corporation, please visit www.proteinsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.